knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 23:28:02 - browse：39892

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： How redistricting in 6 states could affect who controls Congress

hotspot

WSS

How redistricting in 6 states could affect who controls Congress

New CMS data security rules will hurt Medicare, Medicaid research

Medicare Advantage enrollment hits roughly 33.4 million

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Hospitals are piloting generative AI tools as regulators play catch

focus

knowledge

hotspot

In age of alternative facts, a scholarly course on calling out crap

FDA approves Leqembi, a milestone in Alzheimer’s treatment

DIEP, the 'gold standard' of breast reconstruction, is under threat

MD Anderson's Padmanee Sharma responds to research credit suit

Trump demands the U.S. pay no more for drugs than other countries … again

WATCH: Why do our ears pop?

Supreme Court strikes down use of affirmative action

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Medical records are filled with copy

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

hotspot

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

MD Anderson's Padmanee Sharma responds to research credit suit

UPS workers' union leader explains what's at stake as strike edges closer

Another man arrested in connection with shooting at Kansas nightclub

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

New study raises questions about niacin and heart health

focus

hotspot

leisure time

focus